Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Financial Officer | February 09, 2023 | February 13, 2023 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | See Remarks | May 04, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date February 09, 2023 · Filed February 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.59 · Expires 2033-02-08 | Direct | 160,000 |
Reported balance
After 2023-02-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-09 · Grant · Acquired 160,000 · Balance 160,000 F1: This option was granted on February 9, 2023 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 9, 2023 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date.
Spero Therapeutics, Inc.
Report date May 04, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 986,851 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Sale · Disposed 25,240 · Balance 986,851 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 7, 2026 01:53 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 25,240 | $2.51 | $63,352.40 |
DisclosureSEC source: 0001193125-26-209884 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986,851 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:31 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 50,816 | $2.36 | $119,925.76 |
DisclosureSEC source: 0001193125-26-043336 · ownership.xml · nonDerivative · entry 2 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,012,091 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 02:31 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 37,101 | $2.36 | $87,558.36 |
DisclosureSEC source: 0001193125-26-043336 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,062,907 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 498,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001193125-26-038184 · ownership.xml · derivative · entry 3 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,000 Underlying: Common Stock · 498,000 shares Expires 2036-02-02 F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 18,442 | $2.20 | $40,572.40 |
DisclosureSEC source: 0001193125-26-038184 · ownership.xml · nonDerivative · entry 2 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100,008 F2 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 02:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 249,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-038184 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,118,450 F1 · shares: Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 2, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| November 07, 2025 Filed Nov 13, 2025 01:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 40,270 | $2.37 | $95,439.90 |
DisclosureSEC source: 0001193125-25-278370 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 869,450 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on November 13, 2023. F1 · shares: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on November 13, 2023. Read SEC document |
| May 02, 2025 Filed May 7, 2025 00:01 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 185,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-064821 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 909,720 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on May 2, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 01:52 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 20,689 | $0.78 | $16,137.42 |
DisclosureSEC source: 0000950170-25-014859 · ownership.xml · nonDerivative · entry 3 Rajavelu Esther · CIK 0001903716 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724,720 F3 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:52 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014859 · ownership.xml · nonDerivative · entry 2 Rajavelu Esther · CIK 0001903716 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,409 F2 · shares: Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 01:52 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 266,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014859 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,409 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 17,245 | $1.30 | $22,418.50 |
DisclosureSEC source: 0000950170-24-125339 · ownership.xml · nonDerivative · entry 2 Rajavelu Esther · CIK 0001903716 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,270 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on November 13, 2023. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:05 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 23,351 | $1.31 | $30,589.81 |
DisclosureSEC source: 0000950170-24-125339 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,515 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on November 13, 2023. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 01:44 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 119,866 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011490 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,866 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:17 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064189 · ownership.xml · nonDerivative · entry 1 Rajavelu Esther · CIK 0001903716 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on November 6, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0000899243-23-004742 · doc4.xml · derivative · entry 1 Rajavelu Esther · CIK 0001903716 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2033-02-08 F1 · derivative.exercise_date: This option was granted on February 9, 2023 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| January 03, 2022 Filed Jan 10, 2022 21:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $17.82 | $0.00 |
DisclosureSEC source: 0000899243-22-001475 · doc4.xml · derivative · entry 1 Rajavelu Esther · CIK 0001903716 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: This option was granted on January 3, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of January 3, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.